Core Viewpoint - The company has established a dual-track strategy focusing on both invasive and non-invasive medical applications, particularly in the field of brain-computer interfaces (BCIs) [1] Group 1: Non-Invasive Medical Applications - The company is currently integrating existing rehabilitation devices with brain-computer interfaces to enhance product functionality and is actively promoting commercialization [1] - In addition to the medical field, the company is exploring non-medical applications in various sectors, including education, elderly care, and health [1] - In the education sector, the company has launched a brain-computer interface biofeedback system aimed at attention detection and training [1] Group 2: Invasive Medical Applications - The company is constructing a research verification center and an animal testing center for its brain-computer interface technology, which are crucial for its strategic layout in this field [1] - These two centers will create a complete innovation chain from basic research to technology verification and result transformation [1]

Core Viewpoint - The brain-computer interface (BCI) sector in the A-share market has seen significant gains, driven by recent government policies that elevate BCI from a research field to a national industry strategy [1][2]. Group 1: Market Performance - On August 12, stocks in the BCI sector rose sharply, with Mailland increasing by over 18%, Xiangyu Medical by 12%, and Qisheng Technology by 10% [1]. - Other notable stocks in the sector, such as Innovation Medical, Chengyitong, and Beiyikang, also experienced gains [1]. Group 2: Policy Developments - A joint announcement from seven government departments, including the National Health Commission and the Drug Administration, has been made to promote the innovation and development of the BCI industry, marking a significant policy shift [2]. - Multiple policies have been implemented this year to accelerate the clinical application of BCI technology, including the establishment of pricing guidelines for BCI services by the National Medical Insurance Administration [3]. Group 3: Company Strategies - Chengyitong has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, integrating existing rehabilitation devices with BCI for product upgrades and exploring applications in education, elderly care, and health [4]. - Sanbo Brain Science is actively monitoring BCI technology trends and is focusing on invasive and semi-invasive applications, while also planning to establish a brain science innovation fund for industry investment and collaboration [6].

Core Viewpoint - The company has established a dual-track strategy of "invasive and non-invasive" approaches in its business operations [1] Non-Invasive Medical Sector - The company is currently integrating existing rehabilitation equipment with brain-computer interface (BCI) technology to enhance product functionality and is actively promoting commercialization [1] - Beyond the medical field, the company is exploring applications in "non-medical" scenarios, including education, elderly care, and health [1] - In the education sector, the company has launched a BCI biofeedback system aimed at attention detection and training [1] Invasive Medical Sector - The company is constructing a brain-computer interface technology research and validation center along with an animal testing center, which are crucial for its strategic layout in the BCI field [1] - These two centers will create a complete innovation chain from "basic research - technology validation - achievement transformation" [1]

Core Viewpoint - The company has established a dual-track strategy focusing on both invasive and non-invasive medical applications, with ongoing efforts to commercialize its products and explore various non-medical scenarios [1] Group 1: Non-Invasive Medical Applications - The company is currently integrating existing rehabilitation equipment with brain-computer interface (BCI) technology to enhance product functionality [1] - Active progress is being made towards the commercialization of these upgraded products in the serious medical sector [1] Group 2: Non-Medical Applications - The company is exploring applications in non-medical fields such as education, elderly care, and health [1] - In the education sector, the company has launched a brain-computer interface biofeedback system aimed at attention detection and training [1] Group 3: Invasive Medical Applications - The company is constructing a research verification center and an animal testing center for its invasive BCI technology, which is a significant strategic move in the BCI field [1] - These two centers will create a complete innovation chain from basic research to technology validation and result transformation [1]

Group 1 - The company has established a dual-track strategy focusing on both "invasive and non-invasive" brain-computer interface (BCI) technologies [2] - In the non-invasive medical sector, the company is integrating existing rehabilitation devices with brain-machine interfaces to enhance product functionality and is actively promoting commercialization [2] - The company is also exploring applications in "non-medical" scenarios, including education, elderly care, and health, having launched a brain-machine interface biofeedback system for attention detection and training in the education sector [2] Group 2 - In the invasive field, the company is constructing a brain-machine interface technology research verification center and an animal testing center, which are crucial for its strategic layout in the BCI domain [2] - These two centers will create a complete innovation chain from "basic research - technology verification - achievement transformation" [2]